IFNG and metastatic melanoma: Given that defects in the antigen presentation machinery and IFNγ signaling contribute to acquired resistance to immune checkpoint inhibitors (ICIs) [8, 37, 38, 39], we used a TGCA dataset [28] (Table S7) to assess an association between ANGPTL2 mRNA levels and overall survival after treatment with programed cell death‐1 (PD‐1) inhibitors in patients with metastatic melanoma.